Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations.
Journal
Blood
Journal Volume
144
Journal Issue
21
Start Page
2169
End Page
2173
ISSN
1528-0020
Date Issued
2024-11-21
Author(s)
Döhner, Hartmut
DiNardo, Courtney D
Appelbaum, Frederick R
Craddock, Charles
Dombret, Hervé
Ebert, Benjamin L
Fenaux, Pierre
Godley, Lucy A
Hasserjian, Robert P
Larson, Richard A
Levine, Ross L
Miyazaki, Yasushi
Niederwieser, Dietger
Ossenkoppele, Gert
Röllig, Christoph
Sierra, Jorge
Stein, Eytan M
Tallman, Martin S
Wang, Jianxiang
Wierzbowska, Agnieszka
Wei, Andrew H
Löwenberg, Bob
Abstract
The European LeukemiaNet (ELN) genetic risk classifications were developed based on data from younger adults receiving intensive chemotherapy. Emerging analyses from patients receiving less-intensive therapies prompted a proposal for an ELN genetic risk classification specifically for this patient population.
Type
journal article